BioTuesdays
NexGel
Markets

Maxim starts NexGel at buy; PT $6

Maxim Group initiated coverage of NexGel (NASDAQ:NXGL) with a “buy” rating and a price target of $6. The stock closed at $1.81 on Feb. 24. NexGel manufactures, develops, and commercializes topical hydrogel-based...

February 25, 2022
Markets

BTIG starts Oncternal at buy; PT $5

BTIG launched coverage of Oncternal Therapeutics (NASDAQ:ONCT) with a “buy” rating and $5 price target. The stock closed at $1.73 on Feb. 23. Oncternal is a clinical-stage biotechnology company focused on a diverse...

February 24, 2022
Markets

Cantor starts Affimed at OW; PT $12

Cantor Fitzgerald initiated coverage of Affimed N.V. (NASDAQ:AFMD) with an “overweight” rating and 12-month price target of $12. The stock closed at $4.23 on Feb. 22. Affimed, which is one of Cantor’s top picks for...

February 23, 2022
Zosano Logo
Markets

BTIG cuts Zosano to neutral from buy; removes PT

BTIG downgraded Zosano Pharma (NASDAQ:ZSAN) to “neutral” from “buy” and removed its price target after the FDA refused to accept the company’s NDA resubmission for M207 to treat acute migraine. Shares of Zosano, which...

February 23, 2022
vTv Therapeutics Logo
Markets

Cantor starts vTv at OW; PT $5

Cantor Fitzgerald launched coverage of vTv Therapeutics (NASDAQ:VTVT) with an “overweight” rating and 12-month price target of $5. The stock closed at 71 cents on Feb. 17. vTv is developing novel orally administered...

February 18, 2022
oramed
Markets

Cantor starts Oramed at OW; PT $20

Cantor Fitzgerald launched coverage of Oramed Pharmaceuticals (NASDAQ:ORMP) with an “overweight” rating and price target of $20. The stock closed at $10.63 on Feb. 17. Oramed is a developing novel drug formulations for...

February 18, 2022
Collegium Pharma
Markets

Cantor ups Collegium Pharma to OW; PT to $26 from $17

Cantor Fitzgerald upgraded Collegium Pharmaceuticals (NASDAQ:COLL) to “overweight” from “neutral” and raised its price target to $26 from $17, citing its agreement to acquire BioDelivery Sciences International.  Shares...

February 14, 2022
Caribou Biosciences
Markets

Brookline starts Caribou Biosciences at buy; PT $19

Brookline Capital Markets initiated coverage of Caribou Biosciences (NASDAQ:CRBU) with a “buy” rating and 12-to-18-month price target of $19. The stock closed at $10.71 on Feb. 11. Caribou is a leading next...

February 14, 2022
Aerovate Therapeutics
Markets

BTIG starts Aerovate Therapeutics at buy; PT $24

BTIG launched coverage of Aerovate Therapeutics (NASDAQ:AVTE) with a “buy” rating and $24 price target. The stock closed at $9.40 on Feb. 10. Aerovate is focused exclusively on developing a dry powder inhaled...

February 11, 2022
SeqLL
Markets

Maxim starts SeqLL at buy; PT $3

Maxim Group initiated coverage of SeqLL (NASDAQ:SQL) with a “buy” rating and price target of $3. The stock closed at $1.60 on Feb. 8. SeqLL is developing true single molecule sequencing (tSMS), a type of short-read...

February 9, 2022
Know Labs
Markets

Dawson James starts Know Labs at buy; PT $7

Dawson James Securities launched coverage of Know Labs (OTCQB:KNWN) with a “buy” rating and price target of $7. The stock closed at $1.59 on Feb. 7. “Know Labs is driving what could be a significant paradigm shift in...

February 8, 2022
Check Cap
Markets

Dawson James ups Check-Cap to buy; PT $1

Dawson James Securities upgraded Check-Cap (NASDAQ:CHEK) to “buy” from “neutral” and maintained its price target of $1. The stock closed at 60 cents on Feb. 4. The company’s C-Scan is a colorectal cancer screening test...

February 7, 2022
Inozyme Pharma
Markets

HCW starts Inozyme at buy; PT $33

H.C. Wainwright initiated coverage of Inozyme (NASDAQ:INZY) with a “buy” rating and $33 price target. The stock closed at $6.10 on Feb. 4. Inozyme is a rare disease biopharmaceutical company focused on developing...

February 7, 2022
Fusion
Markets

Brookline starts Fusion Pharma at buy; PT $15

Brookline Capital Markets launched coverage of Fusion Pharmaceuticals (NASDAQ:FUSN) with a “buy” rating and $15 price target. The stock closed at $7.53 on Feb. 2. Fusion is a clinical-stage oncology company focused on...

February 2, 2022
Markets

Brookline starts IceCure at buy; PT $5.65

Brookline Capital Markets initiated coverage of IceCure Medical (NASDAQ:ICCM) with a “buy” rating and price target of $5.65. The stock closed at $2.59 on Feb. 1. IceCure is a commercial-stage medical device company...

February 2, 2022
Markets

Stifel starts Vigil Neuroscience at buy; PT $24

Stifel initiated coverage of Vigil Neuroscience (NASDAQ:VIGL) with a “buy” rating and $24 price target. The stock closed at $12.90 on Jan. 31. Vigil is focused on precision medicine approaches to treat dementia, with a...

February 1, 2022